Radioactive drug lutathera takes on brain cancer in early trial
NCT ID NCT05109728
First seen Oct 01, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This phase 1 trial tests a radioactive drug called Lutathera in people with glioblastoma, an aggressive brain cancer. The study includes two groups: newly diagnosed patients receiving Lutathera with standard radiation and chemotherapy, and patients with recurrent glioblastoma receiving Lutathera alone. The main goal is to find the safest dose and check for side effects. About 65 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Col Uni Med Center New York Presby
New York, New York, 10032, United States
-
MD Anderson Cancer Center Uni of Te
Houston, Texas, 77030, United States
-
Novartis Investigative Site
Bron, 69677, France
-
Novartis Investigative Site
Marseille, 13885, France
-
Novartis Investigative Site
Porto, 4200-072, Portugal
-
Novartis Investigative Site
Granada, Andalusia, 18014, Spain
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Barcelona, 08036, Spain
-
Novartis Investigative Site
Madrid, 28041, Spain
-
Novartis Investigative Site
Madrid, 28050, Spain
-
Novartis Investigative Site
Lausanne, 1011, Switzerland
-
Novartis Investigative Site
Zurich, 8091, Switzerland
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
-
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin, 53792-1615, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lutathera (lutetium Lu 177 dotatate)
What this could lead to
If this trial succeeds, it could point toward a new treatment option for glioblastoma, a difficult-to-treat brain cancer.
What could go wrong
This is an early phase 1 trial with only 65 participants, focused on safety and dosing. It is too soon to know if the treatment will be effective or have manageable side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.